• Galera Therapeutics posted a net loss of USD 1.61 million for the quarter ended March 31, 2026, versus a net loss of USD 1.59 million a year earlier.
• Operating loss narrowed to USD 1.66 million from USD 1.96 million, as research and development expense fell to USD 15,000 from USD 93,000.
• General and administrative costs eased to USD 1.64 million from USD 1.87 million, while interest income slipped to USD 49,000 from USD 77,000.
• Cash and cash equivalents totaled USD 5.5 million at March 31, 2026; existing cash is expected to fund operations into first quarter of 2027, with substantial doubt raised about ability to continue as a going concern beyond that point.
• April deal activity included a merger agreement with Obsidian Therapeutics and a planned concurrent financing of about USD 350 million via Series C Non-Voting Convertible Preferred Stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001563577-26-000014), on May 14, 2026, and is solely responsible for the information contained therein.